Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 26 Genitourinary 16 Plasma cell 10 Thoracic 5 Sarcoma 4 Gastrointestinal 4 Head & Neck 3 Tumor-Agnostic 2 Other solid neoplasm 2 Lymphoid 2 Gynecologic 2 Endocrine 2 Dermatologic 2 Other hematologic neoplasm 1 Myeloid 1

Conditions

Osteoporosis 1 Mastocytosis, Systemic 1

Interventions

Cyclophosphamide 261 fludarabine phosphate 233 Azacitidine 182 fludarabine 181 Busulfan 176 Cytarabine 155 Imatinib Mesylate 152 Mycophenolic Acid 148 Tacrolimus 146 Whole-Body Irradiation 142 Peripheral Blood Stem Cell Transplantation 140 Cyclosporine 110 Antilymphocyte Serum 108 Melphalan 107 Methotrexate 105 Filgrastim 101 Decitabine 98 nilotinib 94 venetoclax 79 ruxolitinib 79 Dasatinib 68 Granulocyte Colony-Stimulating Factor 66 Stem Cell Transplantation 63 Thiotepa 60 Radiotherapy 60 thymoglobulin 52 Specimen Handling 49 Etoposide 49 Clofarabine 46 Cord Blood Stem Cell Transplantation 45

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Denosumab × Myeloid × Clear all

NCT03401060 2026-03-31

DenosuMast

Assistance Publique - Hôpitaux de Paris

Phase 3 Completed

Osteoporosis, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡